Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients

Summary

Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. The purpose of this study is to determine whether Clofarabine is safe and effective in the treatment of Acute Myelogenous Leukemia (AML.)

Timeline

Start

2002-05

Primary completion

—

Completion

2004-08

Drugs

Indications